REVVITY, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 104.8 USD | +3.25% |
|
+4.18% | -3.96% |
| 03:52pm | Nephron Adjusts Revvity's Price Target to $124 From $120 | MT |
| 02:00pm | Transcript : Revvity, Inc., Q1 2024 Earnings Call, Apr 29, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Revvity, Inc. (formerly PerkinElmer, Inc.) specializes in designing, manufacturing, and marketing measurement devices and analytical instruments for the healthcare, environmental, scientific research, industry and food sectors. Net sales (including intragroup) break down by family of products as follows:
- medical diagnosis equipment (61%);
- analytical tools and instruments (39%): biological molecular research tools, thermal analysis software, chemical and environmental measurement tools, genetic screening instruments, reagents, etc.
Net sales are distributed geographically as follows: the United States (46.7%), China (14.4%), the United Kingdom (4.1%) and other (34.8%).
Calendar
06:00am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
101.5
USD
Average target price
123.2
USD
Spread / Average Target
+21.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.94% | 12.54B | |
| +8.62% | 219B | |
| +7.14% | 183B | |
| +11.00% | 133B | |
| +25.39% | 108B | |
| +0.27% | 63.06B | |
| +12.90% | 52.02B | |
| +3.96% | 48.2B | |
| +0.35% | 40.37B | |
| +13.52% | 39.35B |
- Stock Market
- Equities
- RVTY Stock
- News Revvity, Inc.
- Revvity Says Court Issued Preliminary Injunction Against Cloud Software Group
